Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study

被引:3
|
作者
Abdallah, Khadidja [1 ]
Claes, Kathleen [2 ,3 ]
Huys, Isabelle [1 ]
Follon, Lennert [1 ]
Calis, Charlotte [1 ]
Simoens, Steven [1 ]
机构
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Onderwijs Navorsing 2 Bus 521,Herestraat 49, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Nephrol & Renal Transplantat Res Grp, Louvain, Belgium
[3] UZ Leuven, Dept Nephrol & Renal Transplantat, Louvain, Belgium
关键词
Financing models; Insulated fund; Private insurance; Early access schemes; Compassionate use; Medical need; Off-label use;
D O I
10.1186/s13023-022-02571-8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Although some jurisdictions have implemented particular adjustments to accommodate often-expensive orphan drugs in their healthcare systems, availability of these drugs remains complex. This study investigates alternative financing models and early access schemes for orphan drugs in the context of the Belgian healthcare system.Methods: Three focus group discussions were held with a panel of eleven experts from the Belgian Drug Reimbursement Committee, the Colleges for Orphan Drugs, the pharmaceutical industry, physicians, ethicists and pharmacists. Retrieved data were pseudonymised, analysed and coded according to the Qualitative Analysis Guide of Leuven.Results: Experts disfavoured the insulated fund as well as private insurance for financing orphan drugs, as, respectively, isolation of a separate budget and a mostly profit-driven mechanism would contradict the Belgian fundamental principle of solidarity. Moreover, an insulated fund could, albeit on a smaller scale, reproduce the same budgetary constraints as the general reimbursement system. As the Special Solidarity Fund is intended for urgent care and exclusively accommodates financial needs subject to eligibility criteria, its design would not allow general financing of orphan drugs. Overall, implementation of an alternative financing model was not endorsed, instead, improving the current reimbursement system was preferred. Suggestions mentioned were; increased collaboration and transparency, robust and quality real-world evidence but also digitalization of data. Alleviating administrative burden and simplifying the admission process of compassionate use program, medical need program and early treatment reimbursement should be prioritized to facilitate early access. Furthermore, a legal framework for off-label use could stimulate proper implementation. Efforts on collaboration of expertise centres and coordination of orphan drug databases across Europe could foster a robust data network to support orphan drug availability in individual countries.Conclusions: This research reveals that reassessing current financing models and early access schemes by eliminating inadequacies, may be more conducive than establishing alternative systems to increase availability of orphan drugs in Belgium. Other jurisdictions may rely on this information to review their own models of early access and financing to cultivate a more sustainable delivery of orphan drugs.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] ACCESS TO ORPHAN DRUGS IN FRANCE: THE CASE OF SIKLOS FOR THE TREATMENT OF SICKLE CELL SYNDROME BEFORE THE COUNCIL OF STATE
    Murteira, S.
    El Hammi, E.
    Kornfeld, A.
    Toumi, M.
    VALUE IN HEALTH, 2014, 17 (07) : A453 - A453
  • [22] The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
    Lee, Dawn
    McCarthy, Grant
    Saeed, Omar
    Allen, Rachel
    Malottki, Kinga
    Chandler, Fleur
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 175 - 187
  • [23] The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
    Dawn Lee
    Grant McCarthy
    Omar Saeed
    Rachel Allen
    Kinga Malottki
    Fleur Chandler
    PharmacoEconomics - Open, 2023, 7 : 175 - 187
  • [24] Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
    Abouarab, Bechara
    Bazarian, Christian
    Ben Chaouch, Zied
    Lo, Andrew W.
    Gonzalez, Guillermo Mourenza
    Novak, Richard
    Vigneault, Frederic
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [25] Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
    Bechara Abouarab
    Christian Bazarian
    Zied Ben Chaouch
    Andrew W. Lo
    Guillermo Mourenza Gonzalez
    Richard Novak
    Frederic Vigneault
    Orphanet Journal of Rare Diseases, 18
  • [26] Application of four pricing models for orphan medicines: a case study for lumasiran
    Rosenberg, Noa
    Manders, Evert
    van den Berg, Sibren
    Deesker, Lisa J.
    Garrelfs, Sander F.
    de Visser, Saco J.
    Groothoff, Jaap W.
    Hollak, Carla E. M.
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [27] Toward Early Stage Dynamic Power Estimation: Exploring Alternative Machine Learning Methods and Simulation Schemes
    Fengler, Philipp
    Nassif, Sani
    Schlichtmann, Ulf
    2024 25TH INTERNATIONAL SYMPOSIUM ON QUALITY ELECTRONIC DESIGN, ISQED 2024, 2024,
  • [28] Exploring pupils' perceptions of teacher racism in their context: A case study of Turkish and Belgian vocational education pupils in a Belgian school
    Stevens, Peter A. J.
    BRITISH JOURNAL OF SOCIOLOGY OF EDUCATION, 2008, 29 (02) : 175 - 187
  • [29] ALTERNATIVE ADIABATIC ELIMINATION SCHEMES FOR FAST VARIABLES - A CASE-STUDY
    THEISS, W
    TITULAER, UM
    ZEITSCHRIFT FUR PHYSIK B-CONDENSED MATTER, 1983, 52 (01): : 75 - 82
  • [30] WELFARE EFFECTS OF ALTERNATIVE WATER RATIONING SCHEMES - A CASE-STUDY
    MERCER, LJ
    MORGAN, WD
    WATER RESOURCES BULLETIN, 1989, 25 (01): : 203 - 210